Advertisement

Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px
Organisation › Details

Oxurion (Group)

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing treatments to preserve vision in patients with diseases affecting the back of the eye. The company has built a diverse portfolio of disease-modifying therapies, including treatments for diabetic eye disease, a leading cause of blindness in people of working age worldwide. Oxurion’s clinical pipeline consists of THR-317, a PlGF inhibitor, for the treatment of diabetic macular edema (DME); THR-149, a plasma kallikrein inhibitor for the treatment of DME; and THR-687, a panRGD integrin antagonist for the treatment of diabetic retinopathy and DME. Further new drug candidates are currently being assessed and developed for the treatment of diabetic eye disease. Oxurion owns the global rights to JETREA® (ocriplasmin), the only pharmacological vitreolysis drug approved for the treatment of symptomatic vitreomacular adhesion (in the U.S.) and vitreomacular traction (outside the U.S.). Oxurion is headquartered in Leuven, Belgium, and is listed on the Euronext Brussels exchange under the symbol THR. In the US, Oxurion NVoperates ThromboGenics inc. as a subsidiary company. *

 

Period Start 2018-09-10 renamed
  Predecessor ThromboGenics (Group)
Products Industry biopharmaceutical
  Industry 2 Jetrea®
Persons Person De Haes, Patrik (ThromboGenics 200808– CEO before Roche Diagnostics)
  Person 2 Buyse, Chris (Fund+ 201610 Managing Partner before ThromboGenics 201203 CFO)
     
Region Region Leuven (Louvain)
  Country Belgium
  City n. a. Leuven
    Address record changed: 2018-09-13
     
Basic data Employees n. a.
  Currency EUR
  Annual sales 7,104,000 (income, consolidated (2016) 2016-12-31)
  Profit -60,348,000 (2016-12-31)
  Cash 113,400,000 (2017-09-30)
     
    * Document for �About Section�: Oxurion N.V.. (9/10/18). "Press Release: Oxurion NV Announces New Euronext Brussels Stock Ticker “OXUR” and Launch of New Website". Leuven.
     
   
Record changed: 2018-09-13

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

More documents for Oxurion (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px




» top